StockData

Mereo BioPharma vs Spruce Biosciences

MREO and SPRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MREO and SPRB compare

Mereo BioPharma is the larger company, worth 1.9 times as much as Spruce Biosciences ($219M against $116M).

Spruce Biosciences scores higher on the StockData Score (3 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMREOSPRB
Size and price
Market cap$219M$116M
Share price$0.275$40.49
Change, 1 year−84.6%−61.9%
Change, 5 years−85.6%−80.4%
Beta (5Y)2.290.12
Employees398
StockData Score
Total score13 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score12 (better)
Dividend score00
Valuation
P/B9.2×1.4× (better)
FCF yield−10.1%–
Profitability
Return on equity−76.6% (better)−106%
Financial health
Debt / equity–0.08
Interest coverage−440.6×−26.6× (better)
Current ratio5.229.23 (better)
Altman Z-score−4.68−1.16 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions7.1%69.7%
Held by insiders0.18%71.7%
Short interest, % of float–65.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.